Phase 2 Open Label, Multicenter Study Evaluating CRG-022, a CD22-directed Autologous CAR T-cell Therapy, in Patients (pts) with Relapsed/refractory (R/R) Large B-cell Lymphoma (LBCL) after CD19-directed CAR T-cell Therapy.Armin Ghobadi,Caron Alyce Jacobson,Joseph McGuirk,Nirali Shah,John Rossi, Tonia Jane Buchholz,Lizamarie Bachier-Rodriguez,John H. Baird,Catherine S. Diefenbach,Umar Farooq,Francisco J. Hernandez-Ilizaliturri,Iris Isufi,Krish Patel,Sattva Swarup Neelapu,Craig Steven Sauter,Jay Y. Spiegel,Michael Timothy Tees,John Timmerman,Ginna Laport,Matthew Joshua FrankJournal of Clinical Oncology（2024）引用 0|浏览15AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
